Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi’s COVID-19 Vaccine Safe and Tolerable, Increases Antibody Titers: Japan PI/II
December 8, 2021
- Sumitomo Dainippon Sets Up Subsidiary in Malaysia, Eyes Latuda Launch
December 8, 2021
- Medicago/GSK’s COVID-19 Vaccine 71% Effective: PII/III
December 8, 2021
- PI Telomelysin Trial for Esophageal Cancer Begins in US: Oncolys
December 8, 2021
- Janssen Files CAR-T Therapy Cilta-Cel for Multiple Myeloma in Japan
December 8, 2021
- EU Panel Backs Tocilizumab for Severe COVID-19: Chugai
December 8, 2021
- Japan Ethical Drug Sales Down 3.2% in October: Crecon
December 8, 2021
- Kobayashi Kako Ditches Turnaround Plan with Manufacturing Transfer to Sawai
December 7, 2021
- Horizon Plants Flag in Japan Soil to Gear Up for Thyroid Eye Disease Trial
December 7, 2021
- Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
- Shionogi Kicks Off COVID-19 Booster Trial in Japan
December 6, 2021
- Mitsubishi Tanabe, Janssen to Copromote Dyskinesia Med in Japan
December 6, 2021
- Bayer Yakuhin President Julio Triana to Double as Bayer Holding Japan Chief
December 6, 2021
- MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
- Sawai to Acquire Kobayashi Kako’s Manufacturing Sites, Staffers
December 3, 2021
- Astellas, Dyno Therapeutics to Collaborate in R&D of Next-Generation AAV Vectors
December 3, 2021
- Shionogi Earns Taiwan Nod for Constipation Treatment Symproic
December 3, 2021
- Enhertu Enters Global PIII for Neoadjuvant Therapy for Breast Cancer: Daiichi Sankyo
December 2, 2021
- Moderna Names Ex-Ferring Japan CEO Rami Suzuki as Japan Chief
December 2, 2021
- Nippon Shinyaku Launches Paid Access Program for Viltepso
December 1, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…